Skip to main content

Table 1 Clinical covariates for the TCGA lung adenocarcinoma cohort in the training and test set

From: An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma

Covariates

Total

Training set

Testing set

P-value

N = 372

N = 186

N = 186

Age, years, no (%)

<=65

174 (46.8)

94 (50.5)

80 (43.0)

0.1767

 

>65

198 (53.2)

92 (49.5)

106 (57.0)

 

Gender, no (%)

Male

176 (47.3)

87 (46.8)

89 (47.8)

0.9173

 

Female

196 (52.7)

99 (53.2)

97 (52.2)

 

Vital status

Alive

258 (69.4)

125 (67.2)

133 (71.5)

0.4311

 

Dead

114 (30.6)

61 (32.8)

53 (28.5)

 

Disease stage, no (%)

I

199 (53.5)

100 (53.8)

99 (53.2)

0.9000

 

II

89 (23.9)

42 (22.6)

47 (25.3)

 
 

III

66 (17.7)

35 (18.8)

31 (16.7)

 
 

IV

17 (4.6)

9 (4.8)

8 (4.3)

 

Lymph node

N0

231 (62.1)

118 (63.4)

113 (60.8)

0.6046

Involvement, no (%)

N1

72 (19.4)

32 (17.2)

40 (21.5)

 
 

N2

58 (15.6)

32 (17.2)

26 (14.0)

 
 

N3

1 (0.3)

0 (0.0)

1 (0.5)

 

M stage, no (%)

M0

266 (71.5)

131 (70.4)

135 (72.6)

0.4400

 

M1

16 (4.3)

10 (5.4)

6 (3.2)

 

T stage, no (%)

T1

112 (30.1)

52 (28.0)

60 (32.3)

0.6320

 

T2

211 (56.7)

108 (58.1)

103 (55.4)

 
 

T3

31 (8.3)

15 (8.1)

16 (8.6)

 
 

T4

16 (8.3)

10 (5.4)

6 (3.2)

 

Smoking status

Nonsmoker

143 (38.4)

66 (35.5)

77 (41.4)

0.3214

 

Smoker

217 (58.3)

113 (60.8)

104 (55.9)

 

Adjuvant treatment

None

255 (68.5)

121 (65.1)

134 (72.0)

0.5530

 

Chemotherapy

68 (18.3)

37 (19.9)

31 (16.7)

 
 

Radiotherapy

20 (5.4)

13 (7.0)

7 (3.8)

 
 

Chemoradiotherapy

27 (7.3)

14 (7.5)

13 (7.0)

 
 

Other

2 (0.5)

1 (0.5)

1 (0.5)

 
  1. Nonsmoker: lifetime nonsmoker or current reformed smoker for > 15 years.